Abstract
Background: The feasibility of a preoperative docetaxel/5′-deoxy-5- fluorouridine (5′-DFUR) regimen for breast cancer patients was examined and the genes related to the response to it was investigated. Patients and Methods: Women with advanced breast cancer were treated with docetaxel (60 mg/m2, day 1) and 5′-DFUR (800 mg/day, on days 1-14) q3 weeks by 4 cycles. Microarray analysis was carried out using preoperative core biopsy samples. Based on the mRNA expression levels, genes related to clinical and pathological responses were selected. Results: The docetaxel/5′-DFUR regimen showed a 86% clinical response rate including 42% complete response, one pathological complete response and one ductal carcinoma in situ component. In microarray analysis, we identified 6 genes, including IGF-1, and derived a predictive formula with 67% accuracy. In addition, χ2 analysis revealed a tendency for good response in ER-negative and Her2/neu-positive cases. Conclusion: Microarray analysis enabled us to predict the pathological response to docetaxel/5′-DFUR chemotherapy.
| Original language | English |
|---|---|
| Pages (from-to) | 2649-2655 |
| Number of pages | 7 |
| Journal | Anticancer research |
| Volume | 27 |
| Issue number | 4 C |
| Publication status | Published - 2007 Jul |
Keywords
- 5′-deoxy-5-fluorouridine
- Docetaxel
- Microarray
- Prediction
- Support vector machine
ASJC Scopus subject areas
- Oncology
- Cancer Research
